Neuromuscular Disorders
FDA/CDC
Firdapse approved: First treatment for rare autoimmune disorder
Amifampridine (Firdapse) has been approved by the FDA for Lambert-Eaton myasthenic syndrome, which affects the nerves’ connection with muscles.
FDA/CDC
CDC: No medical therapy can yet be recommended for acute flaccid myelitis
Updated guidelines find no solid evidence behind any treatment, all which must still be considered anecdotal.
Conference Coverage
Conference News Roundup—American Association of Neuromuscular & Electrodiagnostic Medicine
Conference Coverage
Does Thymectomy Benefit Patients With Anti-MuSK Myasthenia Gravis?
WASHINGTON, DC—Among patients with anti-muscle-specific kinase (MuSK) myasthenia gravis, thymectomy is not associated...
Conference Coverage
Disability in Patients With Stiff Person Syndrome May Progress Faster Than Thought
WASHINGTON, DC—Stiff person syndrome leads to disability if therapy is not initiated early in the disease course,...
Conference Coverage
New Registry Offers Insight Into Opsoclonus-Myoclonus Syndrome
WASHINGTON – Most patients with opsoclonus myoclonus syndrome experience ataxia, among multiple other symptoms.
Video
Planning for ventilator-dependent patients during natural disasters
SAN ANTONIO – Ventilator-dependent patient are especially vulnerable during natural disasters.
Latest News
Neurologic disease eventually affects half of women and one-third of men
Around one-half of women and one-third of men are likely to develop either stroke, dementia, or parkinsonism during their lifetime.
From the Journals
Idiopathic inflammatory myopathies: Muscle biopsy no longer needed?
Myositis-specific antibodies played a key role in predicting whether a patient belonged in a patient cluster.
Conference Coverage
ATTR-ACT shows treatment breakthrough in amyloid cardiomyopathy
MUNICH – Tafamidis is the first-ever disease-modifying therapy for this rapidly progressive and underdiagnosed form of cardiomyopathy.
From the Journals
Spinraza shows motor improvements in older children with SMA type 1